BURLINGTON, Mass., April 10, 2014 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) today announced that an Investigator-Initiated Study evaluating TSO (Trichuris suis ova or CNDO-201) for the treatment of pediatric patients with autism spectrum disorder (ASD) has initiated. The study is being conducted by the Hadassah-Hebrew University Medical Center in Jerusalem, Israel. Dr. Itai Berger, Director of its Neuro-Cognitive Center, is the Principal Investigator of the trial.
Help employers find you! Check out all the jobs and post your resume.
